Zonisamide in the early stage of Parkinson's disease

摘要: Background Zonisamide is one of the anti-parkinsonian agents approved and used in Japan, it improves motor symptoms off time advanced stage Parkinson's disease. However, there no evidence its efficacy early disease. Aim To investigate effect zonisamide on disease. Methods We consecutively recruited patients with less than 3 years disease duration who were treated levodopa/dopa decarboxylase inhibitor only or additional small amounts dopamine agonists. We evaluated severities Unified Disease Rating Scale, non-motor Non-Motor Symptom scale health-related quality daily life 39 items Questionnaire. Patients also themselves Patient Global Impression Improvement index. Serum levels monitored throughout study. After baseline clinical evaluation, received 25 mg open-label zonisamide, for 28 weeks. Results We 13 patients, 11 completed Adjunctive significantly improved Scale part III score after 12th week. The summary index 39-item Questionnaire showed significant changes. Mean plasma stable Two could not complete because adverse events. Conclusions Zonisamide can be expected to safe beneficial as well stage.